Effect of macitentan on haemodynamics in patients with pulmonary arterial hypertension: results from the long-term, randomised, placebo-controlled SERAPHIN trial

被引：0
|
作者：
Torbicki, A. [1 ]
Mehta, S. [2 ]
Perchenet, L. [3 ]
Pulido, T. [4 ]
Sastry, B. K. S. [5 ]
Sitbon, O. [6 ]
Souza, R. [7 ]
Rubin, L. J. [8 ]
Simonneau, G. [6 ]
机构：
[1] Ctr Postgrad Med Educ, Ecz Otwock, Poland
[2] London Hlth Sci Ctr, London, ON, Canada
[3] Actel Pharmaceut Ltd, Allschwil, Switzerland
[4] Natl Inst Cardiol Ignacio Chavez, Mexico City, DF, Mexico
[5] CARE Hosp, Hyderabad, Andhra Pradesh, India
[6] Hop Univ Bicetre, Serv Pneumol, Paris, France
[7] Univ Sao Paulo, Sch Med, Inst Heart, Sao Paulo, Brazil
[8] Univ Calif San Diego, San Diego, CA 92103 USA
来源：
EUROPEAN HEART JOURNAL | 2013年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：186 / 186
页数：1
相关论文
共 50 条
  • [21] Long-term results of the DelIVery for Pulmonary Arterial Hypertension trial
    Gomberg-Maitland, Mardi
    Bourge, Robert C.
    Shapiro, Shelley M.
    Tarver, James H., III
    Zwicke, Dianne L.
    Feldman, Jeremy P.
    Chakinala, Murali M.
    Frantz, Robert P.
    Torres, Fernando
    Bag, Remzi
    Murphy, Jeffrey A.
    Lautenbach, Amy A.
    Morris, Marty
    Peterson, Leigh
    Waxman, Aaron B.
    PULMONARY CIRCULATION, 2019, 9 (04)
  • [22] Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial (vol 151, pg 106, 2017)
    Mehta, S.
    Sastry, B. K. S.
    Souza, R.
    Torbicki, A.
    Ghofrani, H. A.
    Channick, R. N.
    Delcroix, M.
    Pulido, T.
    Simonneau, G.
    Wlodarczyk, J.
    Rubin, L. J.
    Jansa, P.
    Hunsche, E.
    Galie, N.
    Perchenet, L.
    Sitbon, O.
    CHEST, 2018, 153 (05) : 1287 - 1287
  • [23] Macitentan reduces the risk of morbidity and mortality irrespective of the presence or absence of right ventricular (RV) impairment: Results from the randomised SERAPHIN trial in pulmonary arterial hypertension (PAH)
    Sitbon, Olivier
    Channick, Richard N.
    Delcroix, Marion
    Ghofrani, Hossein-Ardeschir
    Jansa, Pavel
    Le Brun, Franck -Olivier
    Mehta, Sanjay
    Perchenet, Loic
    Pulido, Tomas
    Rubin, Lewis J.
    Sastry, B. K. S.
    Simonneau, Gerald
    Souza, Rogerio
    Torbicki, Adam
    Galie, Nazzareno
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [24] Cicletanine in pulmonary arterial hypertension (PAH): Results from a phase 2 randomized placebo-controlled trial
    Waxman, Aaron
    Oudiz, Ronald
    Shapiro, Shelley
    Gomberg-Maitland, Mardi
    Keogh, Anne
    Badesch, David
    Frantz, Robert
    Elliott, C. Gregory
    Gillies, Hunter
    Walker, Gennyne
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [25] Long-term benefits of airway clearance in bronchiectasis: a randomised placebo-controlled trial
    Munoz, Gerard
    de Gracia, Javier
    Buxo, Maria
    Alvarez, Antonio
    Vendrell, Montserrat
    EUROPEAN RESPIRATORY JOURNAL, 2018, 51 (01)
  • [26] Macitentan reduces the risk of morbidity mortality irrespective of the presence or absence of right ventricular (RV) impairment: Results from the randomised SERAPHIN trial in pulmonary arterial hypertension (PAH)
    Sitbon, Olivier
    Channick, Richard N.
    Delcroix, Marion
    Ghofrani, Hossein-Ardeschir
    Jansa, Pavel
    Le Brun, Franck -Olivier
    Mehta, Sanjay
    Perchenet, Loic
    Pulido, Tomas
    Rubin, Lewis J.
    Sastry, B. K. S.
    Simonneau, Gerald
    Souza, Rogerio
    Torbicki, Adam
    Galie, Nazzareno
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [27] Effect of domiciliary oxygen therapy on exercise capacity and quality of life in patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension: a randomised, placebo-controlled trial
    Ulrich, Silvia
    Saxer, Stephanie
    Hasler, Elisabeth D.
    Schwarz, Esther I.
    Schneider, Simon R.
    Furian, Michael
    Bader, Patrick R.
    Lichtblau, Mona
    Bloch, Konrad E.
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54 (02)
  • [28] MACITENTAN TREATMENT EFFECT IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION TAKING SPIRONOLACTONE: POST-HOC ANALYSIS OF THE PHASE 3 SERAPHIN TRIAL
    Safdar, Zeenat
    Jansa, Pavel
    Mehta, Sanjay
    Pulido-Zamudio, Tomas
    Sastry, B. K.
    Sitbon, Olivier
    Souza, Rogerio
    Torbicki, Adam
    Martinez, Eliana
    Zhao, Carol
    Delcroix, Marion
    CHEST, 2021, 160 (04) : 2284A - 2286A
  • [29] Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension
    Spiekerkoetter, Edda
    Sung, Yon K.
    Sudheendra, Deepti
    Scott, Valerie
    Del Rosario, Patricia
    Bill, Matthew
    Haddad, Francois
    Long-Boyle, Janel
    Hedlin, Haley
    Zamanian, Roham T.
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50 (03)
  • [30] Adjusting Overall Survival Estimates of Macitentan in Pulmonary Arterial Hypertension After Treatment Switching: Results from the SERAPHIN Study
    Lilla Di Scala
    Marisa Bacchi
    Bjørn Bayer
    Stefano Turricchia
    Advances in Therapy, 2022, 39 : 4346 - 4358
12345